Immunogenicity and protective efficacy of candidate universal influenza a nanovaccines produced in plants by Tobacco mosaic virus-based vectors

Current Pharmaceutical Design

Volumn 19, Issue 31, 2013, Pages 5587-5600

  Petukhova, Natalia V ^a   Gasanova, Tatiana V ^a   Stepanova, Liudmila A ^b   Rusova, Oxana A ^b   Potapchuk, Marina V ^b   Korotkov, Alexandr V ^b   Skurat, Eugene V ^a   Tsybalova, Liudmila M ^b   Kiselev, Oleg I ^b   Ivanov, Peter A ^a   Atabekov, Joseph G ^a  

^a MOSCOW STATE UNIVERSITY   (Russian Federation)

^b N N BLOKHIN NATIONAL MEDICAL RESEARCH CENTER OF ONCOLOGY   (Russian Federation)

Author keywords

Antibody response; Chimeric particles; Coat protein fusion; Influenza virus; M2e; Plant; Protective antigens; Tobacco mosaic virus; Universal vaccine

Indexed keywords

COAT PROTEIN; CYSTEINE; EPITOPE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G2A; INFLUENZA A NANOVACCINE; INFLUENZA VACCINE; POLYCLONAL ANTISERUM; UNCLASSIFIED DRUG; VIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL NUCLEUS; CODON; CONTROLLED STUDY; DRUG EFFICACY; ELECTRON MICROSCOPY; ELECTROPHORETIC MOBILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNE SYSTEM; IMMUNIZATION; IMMUNOELECTRON MICROSCOPY; IMMUNOGENICITY; IMMUNOGOLD ELECTRON MICROSCOPY; IMMUNOGOLD LABELING; INFLUENZA A (H1N1); LETHAL DOSE; MOUSE; NICOTIANA BENTHAMIANA; NONHUMAN; PLANT; PLANT CELL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHIZOBIUM; TOBACCO MOSAIC VIRUS; VIRION; VIRUS GENOME; VIRUS PARTICLE; VIRUS STRAIN; WESTERN BLOTTING;

ANIMALS; DOGS; EPITOPES; FEMALE; GENETIC VECTORS; HUMANS; IMMUNOGLOBULIN G; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; LETHAL DOSE 50; MADIN DARBY CANINE KIDNEY CELLS; MICE; MICE, INBRED BALB C; MICROSCOPY, ELECTRON; NANOPARTICLES; ORTHOMYXOVIRIDAE INFECTIONS; SURVIVAL RATE; TOBACCO; TOBACCO MOSAIC VIRUS; VIRAL MATRIX PROTEINS;

EID: 84881350232     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128113199990337     Document Type: Article

References (72)

1. Fan J, Liang X, Horton MS, et al. Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys. Vaccine 2004; 22: 2993-3103.
2. Ito T, Gorman OT, Kawaoka Y, Bean WJ, Webster RG. Evolutionary analysis of the influenza A virus M gene with comparison of the M1 and M2 proteins. J Virol 1991; 65: 5491-5498.
3. Mozdzanovska K, Maise K, Furchner M, Gerhard W. Treatment of influenza virus-infected SACID mice with nonneutralizing antibodies specific for the transmembrane proteins matrix 2 and neuraminidase reduces the pulmonary virus titer bur fails to clear the infection. Virology 1999; 254: 138-146.
4. Neirynck S, Deroo T, Saelens X, Vanlandschoot P, Jou WM, Fiers W. A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat Med 1999; 5: 1157-1163.
5. Feng J, Zhang M, Mozdzanowska K, et al. Influenza A virus infection engenders a poor antibody response against the ectodomain of matrix protein 2. Virol J 2006; 3: 102.
6. Slepushkin VA, Katz JM, Black RA, Gamble WC, Rota PA, Cox NJ. Protection of mice against influenza A virus challenge by vaccination with baculovirus-expressed M2 protein. Vaccine 1995; 13: 1399-402.
7. Latham T, Galarza JM. Formation of wild-type and chimeric influenza virus-like particles following simultaneous expression of only four structural proteins. J Virol 2001; 75: 6154-65.
8. Matassov D, Cupo A, Galarza JM. A novel intranasal virus-like particle (VLP) vaccine designed to protect against the pandemic 1918 influenza A virus (H1N1). Viral Immunol 2007; 20: 441-52.
9. Song JM, Wang BZ, Park KM, et al. Influenza Virus-Like Particles Containing M2 Induce Broadly Cross Protective Immunity. PLoS One 2011; 6: e14538.
10. Park KS, Seo YB, Lee JY, et al. Complete protection against a H5N2 avian influenza virus by DNA vaccine expressing a fusion protein of H1N1 HA and M2e. Vaccine 2011; 29: 5481-87.
11. Tompkins SM, Zhao ZC, Lo CY, et al. Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1. Emerg Infect Dis 2007; 13: 426-35.
12. Mozdzanowska K, Feng J, Eid M, et al. Induction of in uenza type A virus-speci c resistance by immunization of mice with a synthetic multiple antigenic peptide vaccine that contains ectodomains of matrix protein 2. Vaccine 2003; 21: 2616-26.
13. Wolf AI, Mozdzanowska K, Williams KL, et al. Vaccination with M2e-based multiple antigenic peptides: characterization of the B cell response and protection efficacy in inbred and outbred mice. PLoS One 2011; 6: e28445.
14. Huleatt JW, Nakaar V, Desai P, et al. Potent immunogenicity and efficacy of a universal vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin. Vaccine 2008; 26: 201-14.
15. Turley CB, Rupp RE, Johnson C, et al. Safety and immunogenicity of a recombinant M2e-flagellin influenza vaccine (STF2.4xM2e) in healthy adults. Vaccine 2011; 29: 5145-52.
16. Ameiss K, Ashraf S, Kong W, et al. Delivery of woodchuck hepatitis virus-like particles presented influenza M2e by recombinant attenuated salmonella displaying a delayed lysis phenotype. Vaccine 2010; 28: 6704-13.
17. Bessa J, Schmitz N, Hinton HJ, Schwarz K, Jegerlehner A, Bachmann MF. Efficient induction of mucosal and systemic immune responses by virus-like particles administered intranasally: implications for vaccine design. Eur J Immunol 2008; 38: 114-26.
18. De Filette M, Jou WM, Birkett A, et al. Universal influenza A vaccine: optimization of M2-based constructs. Virology 2005; 337: 149-61.
19. De Filette M, Fiers W, Martens W, et al. Improved design and intranasal delivery of an M2e-based human influenza A vaccine. Vaccine 2006; 24: 6597-601.
20. De Filette M, Martens W, Smet A, et al. Universal influenza A M2e-HBc vaccine protects against disease even in the presence of pre-existing anti-HBc antibodies. Vaccine 2008; 26: 6503-07.
21. Fiers W, De Filette M, Birkett A, Neirynck S, Min Jou WA. A "universal" human influenza vaccine. Virus Res 2004; 103: 173-6.
22. Mati S, Rinaldi R, Masenga V, Noris E. Efficient production of chimeric human papillomavirus 16 L1 protein bearing the M2e influenza epitope in Nicotiana benthamiana plants. BMC Biotechnol 2011; 11: 106.
23. Ravin NV, Kotlyarov RY, Mardanova ES, et al. Plant-produced recombinant influenza vaccine based on virus-like HBc particles carrying an extracellular domain of M2 protein. Biochemistry (Mosc) 2012; 77: 33-40.
24. Du L, Zhou Y, Jiang S. Research and development of universal influenza vaccines. Microbes Infect 2010; 12: 280-6.
25. Ebrahimi SM, Tebianian M. Influenza A viruses: why focusing on M2e-based universal vaccines. Virus Genes 2011; 42: 1-8.
26. Fiers W, De Filette M, El Bakkouri K, et al. M2e-based universal influenza A vaccine. Vaccine 2009; 27: 6280-3.
27. Rudolph W, Ben-Yedidia T. A universal influenza vaccine: where are we in the pursuit of this Holy Grail? Hum Vaccin 2011; 7: 10-1.
28. Nemchinov LG, Natilla A. Transient expression of the ectodomain of matrix protein 2 (M2e) of avian influenza A virus in plants. Protein Expr Purif 2007; 56: 153-9.
29. Denis J, Costa-Ramirez E, Zhao Y, et al. Development of a universal influenza A vaccine based on the M2e peptide fused to the papaya mosaic virus (PapMV) vaccine platform. Vaccine 2008; 26: 3395-403.
30. Rioux G, Babin C, Majeau N, Leclerc D. Engineering of papaya mosaic virus (PapMV) nanoparticles through fusion of the HA11 peptide to several putative surface-exposed sites. PLoS One 2012; 7: e31925.
31. Savard C, Guérin A, Drouin K, et al. Improvement of the trivalent inactivated flu vaccine using PapMV nanoparticles. PLoS One 2011; 6: e21522.
32. Savard C, Laliberté-Gagné MÈ, Babin C, et al. Improvement of the PapMV nanoparticle adjuvant property through an increased of its avidity for the antigen [influenza NP]. Vaccine 2012; 30: 2535-42.
33. Hanafi LA, Bolduc M, Gagné ME, et al. Two distinct chimeric potexviruses share antigenic cross-presentation properties of MHC class I epitopes. Vaccine 2010; 28: 5617-26.
34. Montague NP, Thuenemann EC, Saxena P, Saunders K, Lenzi P, Lomonossoff GP. Recent advances of cowpea mosaic virus-based particle technology. Hum Vaccin 2011; 7: 383-90.
35. Sainsbury F, Cañizares MC, Lomonossoff GP. Cowpea mosaic virus: the plant virus-based biotechnology workhorse. Annu Rev Phytopathol 2010; 48: 437-55.
36. Lico C, Mancini C, Italiani P, et al. Plant-produced potato virus X chimeric particles displaying an influenza virus-derived peptide activate specific CD8 T cells in mice. Vaccine 2009; 27: 5069-76.
37. Marconi G, Albertini E, Barone P, et al. In planta production of two peptides of the Classical Swine Fever Virus (CSFV) E2 glycoprotein fused to the coat protein of potato virus X. BMC Biotechnol 2006; 6: 29.
38. Marusic C, Rizza P, Lattanzi L, et al. Chimeric plant virus particles as immunogens for inducing murine and human immune responses against human immunodeficiency virus type 1. J Virol 2001; 75: 8434-39.
39. Yang CD, Liao JT, Lai CY, et al. Induction of protective immunity in swine by recombinant bamboo mosaic virus expressing foot-andmouth disease virus epitopes. BMC Biotechnol 2007; 7: 62.
40. Bendahmane M, Koo M, Karrer E, Beachy RG. Display of epitopes on the surface of tobacco mosaic virus: impact of charge and isoelectric point of the epitope on virus-host interactions. J Mol Biol 1999; 290: 9-20.
41. Smith ML, Lindbo JA, Dillard-Telm S, et al. Modified tobacco mosaic virus particles as a scaffolds for display of protein antigens for vaccine applications. Virology 2006; 348: 475-88.
42. Sugiyama Y, Hamamoto H, Takemoto S, Watanabe Y, Okada Y. Systemic production of foreign peptides on the particle surface of tobacco mosaic virus. FEBS Lett 1995; 359: 247-50.
43. Turpen TH, Reinl SJ, Charoenvit Y, Hoffman SL, Fallarme V, Grill LK. Malarial epitopes expressed on the surface of recombinant tobacco mosaic virus. Biotechnology (N Y) 1995; 13: 53-7.
44. Werner S, Marillonnet S, Hause G, Klimyuk V, Gleba Y. Immunoabsorbent nanoparticles based on a tobamovirus displaying protein A. Proc Nat Acad Sci USA 2006; 103: 17678-83.
45. Wu L, Jiang L, Zhou Z, et al. Expression of foot-and-mouth disease virus epitopes in tobacco by a tobacco mosaic virus-based vector. Vaccine 2003; 21: 4390-8.
46. Goelet P, Lomonossoff GP, Butler PJ, Akam ME, Gait MJ, Karn J. Nucleotide sequence of tobacco mosaic virus RNA. Proc Natl Acad Sci USA 1982; 79: 5818-22.
47. Liu W, Zou P, Ding J, Lu Y, Chen YH. Sequence comparison between the extracellular domain of M2 protein human and avian influenza A virus provides new information for bivalent influenza vaccine design. Microbes Infect 2005; 7: 171-7.
48. Ivanov PA, Mukhamedzhanova AA, Smirnov AA, Rodionova NP, Karpova OV, Atabekov JG. The complete nucleotide sequence of Alternanthera mosaic virus infecting Portulaca grandiflora represents a new strain distinct from phlox isolates. Virus Genes 2011; 42: 268-71.
49. Ratcliff F, Martin-Hernandez AM, Baulcombe DC. Tobacco rattle virus as a vector for analysis of gene function by silencing. Plant J. 2001; 25: 237-45.
50. Koo M, Bendahmane M, Lettieri GA, et al. Protective immunity against murine hepatitis virus (MHV) induced by intranasal or subcutaneous administration of hybrids of tobacco mosaic virus that carries an MHV epitope. Proc Natl Acad Sci USA 1999; 96: 7774-9.
51. Orlov VN, Kust SV, Kalmykov PV, Krivosheev VP, Dobrov EN, Drachev VA. A comparative differential scanning calorimetric study of tobacco mosaic virus and of its coat protein ts mutant. FEBS Lett 1998; 433: 307-11.
52. McCormick AA, Corbo TA, Wykoff-Clary S, et al. TMV-peptide fusion vaccines induce cell-mediated immune responses and tumor protection in two murine models. Vaccine 2006; 24: 6414-23.
53. Palmer KE, Benko A, Doucette SA, et al. Protection of rabbits against cutaneous and mucosal papillomavirus infection using recombinant tobacco mosaic virus containing L2 capsid epitopes. Vaccine 2006; 24: 5516-25.
54. Staczek J, Bendahmane M, Gilleland LB, Beachy RN, Gilleland HE Jr. Immunization with a chimeric tobacco mosaic virus containing an epitope of outer membrane protein F of Pseudomonas aeruginosa provides protection against challenge with P. aeruginosa. Vaccine 2000; 18: 2266-74.
55. Jiang L, Li Q, Li M, et al. A modified TMV-based vector facilitates the expression of longer foreign epitopes in tobacco. Vaccine 2006; 24: 109-15.
56. Li Q, Jiang L, Li M, et al. Morphology and stability changes of recombinant TMV particles caused by a cysteine residue in the foreign peptide fused to the coat protein. J Virol Meth 2007; 140: 212-7.
57. Frolova OY, Petrunia IV, Komarova TV, et al. Trastuzumabbinding peptide display by Tobacco mosaic virus. Virology 2010; 407: 7-13.
58. Akamatsu N, Takeda A, Kishimoto M, Kaido M, Okuno T, Mise K. Phosphorylation and interaction of the movement and coat proteins of brome mosaic virus in infected barley protoplasts. Arch Virol. 2007; 152: 2087-93.
59. Atabekov JG, Rodionova NP, Karpova OV, Kozlovsky SV, Novikov VK, Arkhipenko MV. Translational activation of encapsidated potato virus X RNA by coat protein phosphorylation. Virology 2001; 286: 466-74.
60. Champagne J, Laliberté-Gagné ME, Leclerc D. Phosphorylation of the termini of Cauliflower mosaic virus precapsid protein is important for productive infection. Mol Plant Microbe Interact 2007; 20: 648-58.
61. Ivanov KI, Puustinen P, Merits A, Saarma M, Mäkinen K. Phosphorylation down-regulates the RNA binding function of the coat protein of potato virus A. J Biol Chem 2001; 276: 13530-40.
62. Ivanov KI, Puustinen P, Gabrenaite R, et al. Phosphorylation of the potyvirus capsid protein by protein kinase CK2 and its relevance for virus infection. Plant Cell 2003; 15: 2124-39.
63. Fitchen J, Beachy RN, Hein MB. Plant-virus expressing hybrid coat protein with added murine epitope elicits autoantibody response. Vaccine 1995; 13: 1051-7.
64. Van Regenmortel MHV. The antigenicity of tobacco mosaic virus. Philos Trans R Soc Lond B Biol Sci 1999; 354: 559-68.
65. Loor F. Comparative immunogenicities of tobacco mosaic virus, protein subunits, and reaggregated protein subunits. Virology 1967; 33: 215-20.
66. Smith ML, Fitzmaurice WP, Turpen TH, Palmer KE. Display of peptides on the surface of tobacco mosaic virus particles. Curr Top Microbiol Immunol 2009; 332: 13-31.
67. De Filette M, Martens W, Roose K, et al. An influenza A vaccine based on tetrameric ectodomain of matrix protein 2. J Biol Chem 2008; 283: 11382-7.
68. Adler-Moore J, Munoz M, Kim H, et al. Characterization of the murine Th2 response to immunization with liposomal M2e influenza vaccine. Vaccine 2011; 29: 4460-8.
69. Jegerlehner A, Schmitz N, Storni T, Bachmann MF. Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity. J Immunol 2004; 172: 5598-605.
70. Wei G, Meng W, Guo H, et al. Potent neutralization of influenza A virus by a single-domain antibody blocking M2 ion channel protein. PLoS One 2011; 6: e28309.
71. Nimmerjahn F, Ravetch JV. Divergent immunoglobulin G subclasses activity through selective Fc receptor binding. Science 2005; 310: 1510-2.
72. Mozdzanovska K, Zharikova D, Cudic M, Otvos L, Gerhard W. Roles of adjuvant and route of vaccination in antibody response and protection engendered by asynthetic matrix protein 2-based influenza A virus vaccine in the mouse. Virol J 2007; 4: 118.